Abbott Laboratories (ABT)
NYSE: ABT · Real-Time Price · USD
108.52
+1.27 (1.18%)
At close: Nov 13, 2026, 4:00 PM EST
108.19
-0.33 (-0.30%)
After-hours: Nov 13, 2026, 7:59 PM EST
Abbott Laboratories Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 48,229 | 44,328 | 41,950 | 40,109 | 43,653 | 43,075 | |
Revenue Growth | 10.00% | 5.67% | 4.59% | -8.12% | 1.34% | 24.46% |
Cost of Revenue | 20,656 | 19,210 | 18,644 | 17,919 | 19,083 | 18,080 |
Gross Profit | 27,573 | 25,118 | 23,306 | 22,190 | 24,570 | 24,995 |
Selling, General & Admin | 14,422 | 11,630 | 11,109 | 10,385 | 10,703 | 11,006 |
Research & Development | 3,261 | 2,889 | 2,823 | 2,619 | 2,741 | 2,738 |
Amortization of Goodwill & Intangibles | 2,343 | 1,682 | 1,878 | 1,966 | 2,013 | 2,047 |
Operating Expenses | 20,026 | 16,201 | 15,810 | 14,970 | 15,457 | 15,791 |
Operating Income | 7,547 | 8,917 | 7,496 | 7,220 | 9,113 | 9,204 |
Interest Expense | -995 | -493 | -559 | -637 | -558 | -533 |
Interest & Investment Income | 289 | 308 | 344 | 385 | 183 | 43 |
Currency Exchange Gain (Loss) | 30 | 50 | 27 | -41 | -2 | -1 |
Other Non Operating Income (Expenses) | -35 | -42 | -23 | -19 | -85 | 7 |
EBT Excluding Unusual Items | 6,836 | 8,740 | 7,285 | 6,908 | 8,651 | 8,720 |
Merger & Restructuring Charges | -274 | -274 | -129 | -144 | -234 | -509 |
Gain (Loss) on Sale of Assets | - | - | -143 | - | - | - |
Asset Writedown | - | - | - | -100 | -111 | - |
Pretax Income | 6,562 | 8,466 | 7,013 | 6,664 | 8,306 | 8,211 |
Income Tax Expense | 1,861 | 1,942 | -6,389 | 941 | 1,373 | 1,140 |
Earnings From Continuing Operations | 4,701 | 6,524 | 13,402 | 5,723 | 6,933 | 7,071 |
Net Income | 4,701 | 6,524 | 13,402 | 5,723 | 6,933 | 7,071 |
Preferred Dividends & Other Adjustments | 24 | 24 | 2 | 23 | 28 | 29 |
Net Income to Common | 4,677 | 6,500 | 13,400 | 5,700 | 6,905 | 7,042 |
Net Income Growth | -66.53% | -51.49% | 135.09% | -17.45% | -1.94% | 57.43% |
Shares Outstanding (Basic) | 1,739 | 1,741 | 1,740 | 1,740 | 1,753 | 1,775 |
Shares Outstanding (Diluted) | 1,743 | 1,748 | 1,748 | 1,749 | 1,764 | 1,789 |
Shares Change | -0.27% | - | -0.06% | -0.85% | -1.40% | 0.17% |
EPS (Basic) | 2.69 | 3.73 | 7.70 | 3.28 | 3.94 | 3.97 |
EPS (Diluted) | 2.69 | 3.72 | 7.64 | 3.26 | 3.91 | 3.94 |
EPS Growth | -66.22% | -51.31% | 134.36% | -16.62% | -0.76% | 57.38% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 6,757 | 7,395 | 6,351 | 5,059 | 7,804 | 8,648 |
Free Cash Flow Per Share | 3.88 | 4.23 | 3.63 | 2.89 | 4.42 | 4.83 |
Dividend Per Share | 2.520 | 2.400 | 2.240 | 2.080 | 1.920 | 1.820 |
Dividend Growth | 6.78% | 7.14% | 7.69% | 8.33% | 5.50% | 18.95% |
Gross Margin | 57.17% | 56.66% | 55.56% | 55.32% | 56.28% | 58.03% |
Operating Margin | 15.65% | 20.12% | 17.87% | 18.00% | 20.88% | 21.37% |
Profit Margin | 9.70% | 14.66% | 31.94% | 14.21% | 15.82% | 16.35% |
Free Cash Flow Margin | 14.01% | 16.68% | 15.14% | 12.61% | 17.88% | 20.08% |
EBITDA | 11,458 | 12,033 | 10,714 | 10,463 | 12,380 | 12,742 |
EBITDA Margin | 23.76% | 27.15% | 25.54% | 26.09% | 28.36% | 29.58% |
D&A For EBITDA | 3,911 | 3,116 | 3,218 | 3,243 | 3,267 | 3,538 |
EBIT | 7,547 | 8,917 | 7,496 | 7,220 | 9,113 | 9,204 |
EBIT Margin | 15.65% | 20.12% | 17.87% | 18.00% | 20.88% | 21.37% |
Effective Tax Rate | 28.36% | 22.94% | - | 14.12% | 16.53% | 13.88% |